The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
Merck’s high-priced acquisition finally got the nod in the UK for a rare lung condition, and the FDA greenlit an injectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback